BCI: a cost-effective tool in the extended endocrine therapy setting1

BCI may provide cost savings in the extended treatment setting

  • Use of BCI in patients with estrogen receptor-positive, LN- early-stage breast cancer is projected to be cost saving compared with standard management*
  • BCI projected to yield a net cost savings of $1,803 per patient tested (in the 5-year, post-diagnosis population)
  • Savings achieved through projected impact on extended endocrine therapy use and compliance
  • Savings driven by optimization of extended endocrine therapy utilization in patients likely to receive substantial benefit
  • These findings require validation in additional cohorts, including studies of real-world clinical practice

*Two fact-based economic models were developed to project the cost and effectiveness of BCI in a hypothetical population of patients with ER+, LN- breast cancer compared with standard clinicopathologic diagnostic modalities. The models examined cost utility compared with standard practice when used at diagnosis and in patients disease-free at 5 years post diagnosis. Results in the extended endocrine therapy setting are included here.

References
  1. Gustavsen G, et al. Am J Manag Care. 2014;20:e302-e310.
Breast Cancer Index Intended Use and Limitations

The Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test is intended for use in patients diagnosed with estrogen receptor-positive (ER+), lymph node-negative (LN-) or lymph node positive (LN+; with 1-3 positive nodes) early-stage, invasive breast cancer, who are distant recurrence-free. BCI provides: 1) a quantitative assessment of the likelihood of both late (post-5 years) and overall (0-10 year) distant recurrence following an initial 5 years of endocrine therapy (LN- patients) or 5 years of endocrine therapy plus adjuvant chemotherapy (LN+ patients), and 2) prediction of likelihood of benefit from extended (>5 year) endocrine therapy. BCI results are adjunctive to the ordering physician’s workup; treatment decisions require correlation with all other clinical findings.

This test was developed and its performance characteristics determined by Biotheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high complexity clinical laboratory testing.